Peter E. Clark MD
Associate Professor, Urologic Surgery; Residency Program Director, Vanderbilt University Medical Center, Nashville, TennesseeDr. Clark received his undergraduate degree in Biology from Cornell University and went on to complete his medical degree at Harvard Medical School. He completed his urologic residency at the Cleveland Clinic Foundation and subsequently did his urologic oncology fellowship training at the University of Southern California. He is currently Professor and Chairman of the Department of Urology at Carolinas Healthcare System and Chair of Urologic Oncology at the Levine Cancer Institute in Charlotte NC, having moved from Vanderbilt University where he was also the Residency Program Director. Dr. Clark has an active clinical practice focused primarily on bladder and kidney cancer as well as an active interest in the basic sciences, particularly the role of MAPK’s and canonical Wnt signaling on kidney and bladder oncogenesis. Until recently he was Chair of the bladder/Penile cancer guidelines panel for the National Comprehensive Cancer Network (NCCN) and is a member of non-muscle invasive bladder cancer and small renal mass guidelines panels for the American Urologic Association (AUA). He is serving as the representative for the Southeast Section of the AUA to the AUA Foundation Research Council, the Research, Education, and Communication Committee, the Judicial and Ethics Committee, the Practice Guidelines Committee (where he serves as Vice Chairman), and is on the editorial boards for the Journal of Urology, BJUI, Urologic Oncology, and UROLOGY. He serves on the Examination Committee for the American Board of Urology. He is also an active member of the Society of Urologic Oncology (where he recently was chair of the Fellowship Committee), The Society of Academic Urologists, and the Society of Basic Urologic Research. He has over 170 publications in both the clinical and basic sciences.
Disclosures
Dr. Clark reports no diclosures.Recent Contributions to PracticeUpdate:
- Lymphadenectomy at Time of Cytoreductive Nephrectomy for Metastatic RCC Does Not Improve Survival
- Enlarged Retroperitoneal Lymph Nodes Predict Pathological Nodal Involvement for Renal Cell Carcinoma
- End-Stage Renal Disease After Renal Surgery in Patients With Normal Preoperative Kidney Function
- ESRD After Renal Surgery: Partial Nephrectomy Is Protective, but to What Degree and Consequence?
- Prognostic Model for Survival in Metastatic Renal Cell Carcinoma
- Percutaneous Cryoablation vs Partial Nephrectomy: Cost Comparison of T1a Tumors
- Nephron-Sparing Techniques Decrease the Risk for Cardiovascular Events in Patients With Renal Mass
- MY APPROACH to Diagnosing and Managing Intradiverticular Tumours
- Adverse Outcomes Associated With Surgery of Small Renal Masses
- Utilization of Cytoreductive Nephrectomy and Patient Survival in the Targeted Therapy Era